Administration occupational activities
Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns
Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act
Controversial Stanford Professor Jay Bhattacharya Nominated by Trump to Lead NIH Amid Criticism Over Pandemic Views
Jay Bhattacharya, NIH Director Nomination, COVID-19 Pandemic Response Critic, Stanford University Professor, Trump Administration, Public Health Research, Controversial Appointment
Medtronic Advances Diabetes Management with FDA Clearance of InPen App and Launch of Smart MDI System
Medtronic, FDA clearance, InPen app, Smart MDI system, diabetes management, insulin therapy, continuous glucose monitoring (CGM), Simplera CGM
RFK Jr.’s HHS Nomination: A Potential Threat to the Biopharma Industry
RFK Jr., HHS nomination, biopharma industry, vaccine skepticism, health policies, Trump administration
Biopharma Industry Alarmed by Prospect of RFK Jr. Shaping FDA Policies Under Trump Administration
RFK Jr., FDA, Trump Administration, Biopharma, Healthcare Policy, Agriculture Policy
Enhancing GI Tolerability of GLP-1 Receptor Agonists: A Path to Improved Therapeutic Outcomes
GLP-1 receptor agonists, gastrointestinal tolerability, therapeutic strategies, diabetes management, obesity treatment
Glooko Secures $100 Million Funding to Enhance Diabetes Management Platform Under New Leadership
Glooko, diabetes management, healthcare technology, funding, new leadership
WHO Publishes First Guidance to Combat Antibiotic Pollution from Manufacturing
WHO, antibiotic pollution, antimicrobial resistance (AMR), wastewater management, solid waste management, pharmaceutical manufacturing, environmental health
Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials
Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.
Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials
Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management